TrialBone marrow transplantation2022

Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial.

Jürgen Finke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.